ClinicalTrials.gov
ClinicalTrials.gov Menu

Stem Cell Coated Fistula Plug in Patients With Crohn's RVF

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03220243
Recruitment Status : Active, not recruiting
First Posted : July 18, 2017
Last Update Posted : November 7, 2018
Sponsor:
Information provided by (Responsible Party):
Amy L Lightner, Mayo Clinic

Brief Summary:

The purpose of this study is to determine the safety of using an autologous mesenchymal stromal cell (MSC) coated fistula plug in people with rectovaginal fistulizing Crohn's disease. This is an autologous product derived from the patient and used only for the same patient. Participants will be in this study for two years. There is potential to continue to monitor participants' progress with regular visits as part of standard of care. All study visits take place at Mayo Clinic and Rochester, MN.

The study visit schedule is as follows:

Visit 1 (Week -6) - Screening visit: exam under anesthesia and surgery to assess eligibility of fistula tract, take fat biopsy, if eligible, and fecal diversion.

Visit 2 (Week 0; Day 0), exam under anesthesia for stem cell coated fistula plug placement Visit 3 (Week 0; Day 1) Visit 4 (Week 2; Month 1) Visit 5 (Week 4; Month 1) Visit 6 (Week 8; Month 2) Visit 7 (Week 12; Month 3) Visit 8 (Week 24; Month 6) Visit 9 (Week 52; Month 12). Visit 10 (Week 104, Month 24)


Condition or disease Intervention/treatment Phase
Fistula Vagina Crohn Disease Drug: MSC-AFP Phase 1

Detailed Description:

The Investigators propose to study the safety of autologous mesenchymal stromal cell transfer using a biomatrix (the Gore Bio-A174; Fistula Plug) in a Phase I study using a single dose of 20 million cells. Fifteen adult patients with refractory, rectovaginal fistulizing Crohn's disease will be enrolled. Participants will undergo standard adjuvant therapy including drainage of infection and placement of a draining seton with continuation of pre-existing anti-Crohn's therapy. If the participant is not currently diverted, then participants will undergo a laparoscopic diversion with a loop ileostomy. Six weeks post placement of the draining seton, the seton will be replaced with the MSC loaded Gore Bio-A fistula plug as per current clinical practice. The participants will be subsequently followed for fistula response and closure for 24 months. This is an autologous product derived from the patient and used only for the same patient.

Participants will be screened at outpatient clinic visits and interested qualified participants will be offered participation in the trial and consented. At the first study visit (Visit 1; Screening visit), the patient will be evaluated and assessed. Six weeks post placement of the draining seton, the seton will be replaced with the MSC loaded Gore Bio-A fistula plug. Participants will return on: Day 1, Week 2, Week 4, Week 8, Week 12, Week 24, Week 52, and Week 104.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Rectovaginal Fistulizing Crohn's Disease
Actual Study Start Date : October 19, 2017
Estimated Primary Completion Date : July 20, 2019
Estimated Study Completion Date : July 20, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: MSC-AFP Single Treatment Group
Eligible patients will be treated, single treatment group, no placebo arm.
Drug: MSC-AFP
Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.
Other Name: • mesenchymal stromal cell coated fistula plug




Primary Outcome Measures :
  1. Number of participants with treatment-related adverse events (safety and toxicity). [ Time Frame: 0-24 months ]

    Primary Outcome Measure:

    1.Number of participants with treatment-related adverse events (safety and toxicity).

    Participants will have a health assessment and blood work measured at each study visit to monitor for adverse events, such as worsening of the perinal fistulizing disease, abnormal laboratory values, or significant abnormalities in physical examination. The Outcome Measure will be the number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment



Secondary Outcome Measures :
  1. Number of participants with response to the treatment regarding potential cessation of drainage from their fistula. [ Time Frame: 3-24 months ]
    Participants will have a clinical assessment of fistula drainage. Participants will be assessed during an office examination if their fistula is draining or not. The Outcome Measure will be the presence or absence of fistula drainage.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Rectovaginal fistula, females only eligible
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Females 18-65 years of age.
  2. Residents of the United States.
  3. Crohn's disease with single or multiple draining complex rectovaginal fistulae for at least three months despite standard therapy
  4. Concurrent therapies with corticosteroids, 5-ASA drugs, thiopurines, MTX, antibiotics, and anti-TNF therapy are permitted.
  5. All patients should have undergone a colonoscopy in last 12 months to rule out malignant or premalignant condition
  6. Have no contraindications to MR evaluations: e.g. pacemaker or magnetically active metal fragments, claustrophobia
  7. Ability to comply with protocol
  8. Competent and able to provide written informed consent
  9. Must have failed standard medical therapy including anti-TNF agents
  10. Currently with diverting ileostomy or accepting of diverting ileostomy at time of stem cell loaded plug placement.

Exclusion Criteria

  1. Inability to give informed consent.
  2. Clinically significant medical conditions within the six months before administration of MSCs: e.g. myocardial infarction, active angina, congestive heart failure or other conditions that would, in the opinion of the investigators, compromise the safety of the patient.
  3. Specific exclusions; Evidence of hepatitis B, C, or HIV
  4. History of cancer including melanoma (with the exception of localized skin cancers)
  5. Investigational drug within thirty (30) days of baseline
  6. A resident outside the United States
  7. Pregnant or breast feeding.
  8. History of clinically significant auto-immunity (other than Crohn's disease) or any previous example of fat-directed autoimmunity
  9. Previous allergic reaction to a perianal fistula plug.
  10. Allergic to local anesthetics
  11. Pregnant patients or trying to become pregnant.
  12. entero-vesicular or multiple concurrent perianal tracts

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03220243


Locations
United States, Minnesota
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Investigators
Principal Investigator: Amy L Lightner Mayo Clinic

Responsible Party: Amy L Lightner, Principal Investigator, Mayo Clinic
ClinicalTrials.gov Identifier: NCT03220243     History of Changes
Other Study ID Numbers: 17-002892
First Posted: July 18, 2017    Key Record Dates
Last Update Posted: November 7, 2018
Last Verified: November 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Crohn Disease
Fistula
Vaginal Fistula
Inflammatory Bowel Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Pathological Conditions, Anatomical
Vaginal Diseases
Genital Diseases, Female